CEL-SCI to Present New Data for Multikine Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

BusinesswireSep 10 21:32

The UK's MHRA Grants CEL-SCI's Multikine A Product Specific Waiver For The Treatment Of Head And Neck Cancer In A Pediatric Population Of People Up To 18 Years Of Age

BenzingaSep 4 21:03

CEL-SCI Q3 2024 Adj EPS $(0.14) Misses $(0.11) Estimate

BenzingaAug 15 20:04

Express News | CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

BreakingsAug 15 20:00

CEL-SCI 3Q Loss/Shr 14c >CVM

Dow JonesAug 15 20:00

Cel-Sci: Fiscal Q3 Earnings Snapshot

Yahoo FinanceAug 15 17:09